BYOMass to Participate in BIO-Europe Digital 2021

MASSACHUSETTS, September 30, 2021 — BYOMass, Inc., a biotech company developing selective TGF-β superfamily therapeutics, today announced that it will be participating in the BIO-Europe® Digital 2021 Conference, taking place virtually October 25 to 28. Members of the BYOMass business development team will participate in partnering activities at this conference.

To schedule a meeting, please use the BIO-Europe partnering portal or contact us.

The international BIO-Europe® 2021 gathering will be held digitally to bring the global biopharma and investment leaders together to build partnerships that facilitate innovation and medical breakthroughs with four days of presentations and productive one-on-one partnering meetings.

About BYOMass

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Selectively targeting specific members and pathways within the TGF-β superfamily has the potential to be a meaningful class of therapeutics within oncology, inflammatory/immune, fibrotic, and metabolic diseases.

Contacts

Corporate Contact: Pete Leone, MBA, Chief Business Officer, BYOMass, Inc., info@byomasstx.com

For Media Only: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091